Non-clinical and clinical characterization of a novel acting thrombolytic: Alfimeprase

Pathophysiology of Haemostasis and Thrombosis

Volumn 34, Issue 4-5, 2006, Pages 215-220

  Deitcher, Steven R ^a,b   Toombs, Christopher F ^a  

^a Nuvelo   (United States)

^b NONE   (United States)

Author keywords

Alfimeprase; Fibrinolysis; Thrombolysis; Thrombosis; Urokinase

Indexed keywords

ALFIMEPRASE; ALPHA 2 MACROGLOBULIN; ALTEPLASE; CATHFLO ACTIVASE; FIBRINOLYTIC AGENT; RETEPLASE; STREPTOKINASE; THROMBIN; TISSUE PLASMINOGEN ACTIVATOR; UROKINASE;

ACUTE CORONARY SYNDROME; AGKISTRODON; ANGIOGRAPHY; ANIMAL EXPERIMENT; ANIMAL MODEL; BLEEDING; BLOOD CLOT LYSIS; BRAIN HEMORRHAGE; CAROTID ARTERY THROMBOSIS; CATHETER INFECTION; CENTRAL VENOUS CATHETER; CLINICAL ARTICLE; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; FIBRINOLYSIS; HEADACHE; HEMATOMA; HUMAN; HYPOTENSION; LIMB ISCHEMIA; LUNG EMBOLISM; MAJOR CLINICAL STUDY; NONHUMAN; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; RAT; SNAKE; THROMBOEMBOLISM; THROMBOSIS; TREATMENT OUTCOME; VASCULAR ACCESS DEVICE;

ANIMALS; ARTERIAL OCCLUSIVE DISEASES; CATHETERIZATION, CENTRAL VENOUS; HUMANS; METALLOENDOPEPTIDASES; PERIPHERAL VASCULAR DISEASES; SNAKE VENOMS; THROMBOLYTIC THERAPY;

EID: 33646765794     PISSN: 14248832     EISSN: None     Source Type: Journal    
DOI: 10.1159/000092427     Document Type: Conference Paper

References (12)

1. Ahmed NK, Tennant KD, Markland FS, Lacz JP: Biochemical characteristics of fibrolase, a fibrinolytic protease from snake venom. Haemostasis 1990;20:147-154.
2. Swensen S, Markland FS, Toombs C: Fibrolase; in Barrett AJ (ed): Handbook of Proteolytic Enzymes, ed 2. Elsevier, 2004.
3. Manning MC: Sequence analysis of fibrolase, a fibrinolytic metalloproteinase from Agkistrodon contortrix contortrix. Toxicon 1995;33: 1189-1200.
4. Randolph A, Chamberlain SH, Chu HL, Retzios AD, Markland FS Jr, Masiarz FR: Amino acid sequence of fibrolase, a direct-acting fibrinolytic enzyme from Agkistrodon contortrix contortrix venom. Protein Sci 1992;1:590-600.
5. Retzios AD, Markland FS: Fibrinolytic enzymes from the venoms of Agkistrodon contortrix contortrix and Crotalus basiliscus basiliscus: cleavage site specificity towards the alpha-chain of fibrin. Thromb Res 1994;74: 355-367.
6. Pretzer D, Schulteis BS, Smith CD, Vander VD, Mitchell JW, Manning MC: Stability of the thrombolytic protein fibrolase: effect of temperature and pH on activity and conformation. Pharm Res 1991;8:1103-1112.
7. Barrett AJ: Alpha-2 macroglobulin; in Barrett AJ (ed): Methods in Enzymology. Academic Press, Inc., 1981.
8. Toombs CF: Alfimeprase; in Sasahara AA, Loscalzo J (eds): New Therapeutic Agents in Thrombosis and Thrombolysis, ed 2. Marcel Dekker, 2003.
9. Deitcher SR, Jaff MR: Pharmacologic and clinical characteristics of thrombolytic agents. Rev Cardiovasc Med 2003;3(suppl 2):S25-S33.
10. Risius B, Zelch MG, Graor RA, Geisinger MA, Smith JA, Piraino DW: Catheter-directed low dose streptokinase infusion: a preliminary experience. Radiology 1984;150:349-355.
11. Working Party on Thrombolysis in the Management of Limb Ischemia: Thrombolysis in the management of lower limb peripheral arterial occlusion - a consensus document. Am J Cardiol 1998;81:207-218.
12. Deitcher SR, Fesen MR, Kiproff PM, Hill PA, Li X, McCluskey ER, Semba CP: The safety and efficacy of alteplase (t-PA) for restoring function in occluded central venous catheters: results of the cardiovascular thrombolytic to open occluded lines trial. J Clin Oncol 2002; 20:317-324.